[go: up one dir, main page]

BRPI0508224A - composto ou um sal farmaceuticamente aceitável do mesmo, cepa de actinomiceto, isolado de uma cepa, métodos para a produção de um macrolìdeo e de um composto, produto, composição, métodos de tratamento de um mamìfero e de um distúrbio neurológico, e, uso de um composto - Google Patents

composto ou um sal farmaceuticamente aceitável do mesmo, cepa de actinomiceto, isolado de uma cepa, métodos para a produção de um macrolìdeo e de um composto, produto, composição, métodos de tratamento de um mamìfero e de um distúrbio neurológico, e, uso de um composto

Info

Publication number
BRPI0508224A
BRPI0508224A BRPI0508224-2A BRPI0508224A BRPI0508224A BR PI0508224 A BRPI0508224 A BR PI0508224A BR PI0508224 A BRPI0508224 A BR PI0508224A BR PI0508224 A BRPI0508224 A BR PI0508224A
Authority
BR
Brazil
Prior art keywords
compound
methods
strain
macrolide
isolated
Prior art date
Application number
BRPI0508224-2A
Other languages
English (en)
Inventor
Mia Haruna Yoshino Summers
Edmund Idris Graziani
Margaret M Leighton
Kevin Pong
Roger Alan Kele
David P Labeda
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34919496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0508224(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0508224A publication Critical patent/BRPI0508224A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

COMPOSTO OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, CEPA DE ACTINOMICETO, ISOLADO DE UMA CEPA, MéTODOS PARA A PRODUçãO DE UM MACROLIDEO E DE UM COMPOSTO, PRODUTO,COMPOSIçãO, MéTODOS DE TRATAMENTO DE UM MAMIFERO E DE UM DISTúRBIO NEUROLóGICO, E, USO DE UM COMPOSTO A invenção refere-se,em parte, a compostos macrolideos, a copas de actinomiceto para a sua produção e a composições farmacêuticas contendo os mesmos.
BRPI0508224-2A 2004-03-02 2005-02-25 composto ou um sal farmaceuticamente aceitável do mesmo, cepa de actinomiceto, isolado de uma cepa, métodos para a produção de um macrolìdeo e de um composto, produto, composição, métodos de tratamento de um mamìfero e de um distúrbio neurológico, e, uso de um composto BRPI0508224A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54948004P 2004-03-02 2004-03-02
PCT/US2005/005895 WO2005085257A1 (en) 2004-03-02 2005-02-25 Macrolides and methods for producing same

Publications (1)

Publication Number Publication Date
BRPI0508224A true BRPI0508224A (pt) 2007-07-17

Family

ID=34919496

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508224-2A BRPI0508224A (pt) 2004-03-02 2005-02-25 composto ou um sal farmaceuticamente aceitável do mesmo, cepa de actinomiceto, isolado de uma cepa, métodos para a produção de um macrolìdeo e de um composto, produto, composição, métodos de tratamento de um mamìfero e de um distúrbio neurológico, e, uso de um composto

Country Status (21)

Country Link
US (3) US7247650B2 (pt)
EP (1) EP1720886A1 (pt)
JP (2) JP5032974B2 (pt)
KR (1) KR20070009578A (pt)
CN (1) CN1934117A (pt)
AR (1) AR049681A1 (pt)
AU (1) AU2005219822A1 (pt)
BR (1) BRPI0508224A (pt)
CA (1) CA2556622A1 (pt)
CR (1) CR8568A (pt)
EC (1) ECSP066822A (pt)
GT (1) GT200500035A (pt)
IL (1) IL177605A0 (pt)
NO (1) NO20064034L (pt)
PA (1) PA8624601A1 (pt)
PE (1) PE20051143A1 (pt)
RU (1) RU2006129647A (pt)
SG (1) SG150518A1 (pt)
TW (1) TW200602347A (pt)
WO (1) WO2005085257A1 (pt)
ZA (1) ZA200607347B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507752B2 (en) * 2004-06-03 2009-03-24 Wyeth Biosynthetic gene cluster for the production of a complex polyketide
US7595187B2 (en) * 2004-11-12 2009-09-29 Wyeth Elaiophylin biosynthetic gene cluster
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
RU2008132779A (ru) * 2006-03-07 2010-04-20 Вайет (Us) Аналоги меридамицина для лечения нейродегенеративных заболеваний
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
US7709593B2 (en) 2006-07-28 2010-05-04 Eastman Chemical Company Multiple feeds of catalyst metals to a polyester production process
US20080262228A1 (en) * 2006-11-28 2008-10-23 Wyeth Metabolites of 5-fluoro-8- quinoline and methods of preparation and uses thereof
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
MX2009008105A (es) * 2007-01-29 2010-03-03 Wyeth Corp Ligando de inmunofilina ds y metodos para modular la inmunofilina y la actividad de canal de calcio.
US20100022766A1 (en) * 2008-07-25 2010-01-28 Wyeth Biosynthetic gene cluster for the production of a complex polyketide
CN102174438B (zh) * 2011-01-26 2012-07-25 南京大学 新大环内酯及其制备方法和应用
CN105456298A (zh) * 2015-12-01 2016-04-06 中国人民解放军第二军医大学 草苔虫总内酯抗老年痴呆活性及其应用
CN110051680B (zh) * 2018-01-19 2022-02-18 沈阳福洋医药科技有限公司 一种用于预防和/或治疗阿尔茨海默病的药物、组合产品及其应用
AU2019209740A1 (en) 2018-01-19 2020-09-10 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Use of carrimycin or active ingredient thereof
CN114591286B (zh) * 2021-04-12 2023-05-23 南京大学 新型大环内酯化合物acautalides A-C及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975372A (en) 1989-01-13 1990-12-04 Merck & Co., Inc. Microbial transformation product of L-683,590
EP0528452A1 (en) * 1991-06-19 1993-02-24 Merck & Co. Inc. Immunomycin enzymatic and/or microbial methylation products
GB9302016D0 (en) * 1993-02-02 1993-03-17 Sandoz Ltd Compounds
US5798355A (en) * 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US6118521A (en) * 1996-01-02 2000-09-12 Lj Laboratories, L.L.C. Apparatus and method for measuring optical characteristics of an object
US6242468B1 (en) 1997-02-27 2001-06-05 Jia-He Li Carbamate and urea compositions and neurotrophic uses
JP3511361B2 (ja) * 1997-08-04 2004-03-29 セイコーインスツルメンツ株式会社 走査プローブ顕微鏡
US6111650A (en) * 1997-08-14 2000-08-29 Rawicz; Andrew Method and apparatus for color matching of slightly colored translucent objects such as teeth and dental prosthesis, in particular
BRPI0508084A (pt) * 2004-03-02 2007-07-17 Wyeth Corp método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo
CA2590254A1 (en) * 2004-12-20 2006-06-29 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
TW200628152A (en) * 2004-12-20 2006-08-16 Wyeth Corp Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorsers

Also Published As

Publication number Publication date
IL177605A0 (en) 2006-12-10
ECSP066822A (es) 2006-11-24
PE20051143A1 (es) 2006-02-06
SG150518A1 (en) 2009-03-30
WO2005085257A1 (en) 2005-09-15
CN1934117A (zh) 2007-03-21
EP1720886A1 (en) 2006-11-15
US20070299019A1 (en) 2007-12-27
US7247650B2 (en) 2007-07-24
NO20064034L (no) 2006-11-08
CA2556622A1 (en) 2005-09-15
JP5032974B2 (ja) 2012-09-26
JP2012153699A (ja) 2012-08-16
AR049681A1 (es) 2006-08-30
AU2005219822A1 (en) 2005-09-15
PA8624601A1 (es) 2006-06-02
TW200602347A (en) 2006-01-16
GT200500035A (es) 2005-10-24
ZA200607347B (en) 2010-02-24
CR8568A (es) 2007-02-05
US20050197379A1 (en) 2005-09-08
US20110144176A1 (en) 2011-06-16
RU2006129647A (ru) 2008-04-10
JP2007526307A (ja) 2007-09-13
KR20070009578A (ko) 2007-01-18

Similar Documents

Publication Publication Date Title
BRPI0508224A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, cepa de actinomiceto, isolado de uma cepa, métodos para a produção de um macrolìdeo e de um composto, produto, composição, métodos de tratamento de um mamìfero e de um distúrbio neurológico, e, uso de um composto
BR112012013431A8 (pt) composto, composição farmacêutica e seu uso
SA519401647B1 (ar) y مركبات ببتيد تيروسين-تيروسين الحلقية المقترنة بجسم مضاد كمعدلات لمستقبلات الببتيد العصبي
UY30711A1 (es) Nuevos derivados de 1,4-benzotiepina-1, 1-cioxido, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.-
BRPI0610359B8 (pt) compostos de diaril-hidantoína, suas composições farmacêuticas e sais farmaceuticamente aceitáveis
CL2011000124A1 (es) Compuestos derivados de 3-aril-4-heterociclil-pirazoles, inhibidores de proteina quinasa b-raf; metodo de inhibicion in vitro de la proteina quinasa b-raf; composicion farmaceutica; producto de combinacion farmaceutica; y su uso para el tratamiento del cancer.
WO2006113909A3 (en) Humanized anti-cd70 binding agents and uses thereof
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
BRPI0513029A (pt) método para produzir uma proteìna de eritropoietina carbamilada, proteìna de eritropoietina carbamilada, composto, composição farmacêutica, métodos de tratamento de uma doença ou condição crÈnica, sub-crÈnica e aguda e de tratamento de uma doença do sistema nervoso central ou sistema nervoso periférico, e, uso de um composto
TNSN08140A1 (pt)
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
BR112012020273A2 (pt) Compostos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno e pirazolotiazol como pontencializadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica
EP2490537A4 (en) ALLOSTERIC MGLUR4 POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS
BRPI0715746B8 (pt) composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica os compreendendo
WO2011057208A3 (en) Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
TW200630336A (en) Novel compounds
TW200745003A (en) Novel compounds
TW200621690A (en) Novel compounds
BR112014012396A2 (pt) inibidores de pirazina quinase
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
MXPA05008688A (es) Derivados tetraciclicos de pirazol como inhibidores de la cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
WO2009038385A3 (en) Novel compounds having indazole frameworks, methods for preparing the same and pharmaceutical composition comprising the same
EP2131849A4 (en) COMPOSITIONS AND METHODS OF DISTRIBUTING AGENTS AGAINST CANCER
PH12022550441A1 (en) Azaheteroaryl compound and application thereof
WO2022106897A3 (en) Methods and composition for kras modifications

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.